Bibliographe

American Cancer Society www.cancer.org

National Cancer Institutewww.cancer.gov

World Health Organization -www.who.int

European Society for Medical Oncology www.esmo.org

1. Fisher B, et al. Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy,

Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer.
New England Journal of Medicine. 2002.i

Giuliano AE, et al. Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast
(Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and
Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer, 2002)Cancer and
Sentinel Node Metastasis: A Randomized Clinical Trial. Journal of the American Medical
Association. 2011.

2. Alderman AK, et al. Long-term Results of Implant Reconstruction Using One of Two Different
Techniques. JAMA Surgery. 2013.

1. Andre F, et al. Adjuvant Chemotherapy in Early Breast Cancer: Evidence-Based Practice. J Clin
Oncol. 2006.

1. Baselga J, et al. Relationship between tumor biomarkers and efficacy in the NeoSphere study
of pertuzumab plus trastuzumab in HER2-positive breast cancer. Breast Cancer Res Treat.
2013.

2. Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast
cancer. N Engl J Med. 2015.

1. Denduluri N, et al. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for
Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018.

3. Cardoso F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast
Cancer (ABC 4). Ann Oncol. 2018.

1. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus
tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first
results of the ATAC randomised trial. Lancet. 2002.

2. Fisher B, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical
Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998.

3. Finn RS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016.

1. 4. Hortobagyi GN, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced

Breast Cancer. N Engl J Med. 2016
 2. . Baselga J, et al. Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast
Cancer. N Engl J Med. 2012.

3. Robson M, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA
Mutation. N Engl J Med. 2017.

1. Piccart-Gebhart MJ, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast

Cancer. N Engl J Med. 2005.

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after
breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of
individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011.

2. Fisher B, et al. Effect of preoperative chemotherapy on local-regional disease in women with

operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J
Clin Oncol. 1997.

3. Hartsell WF, et al. Randomized Trial of Short- Versus Long-Course Radiotherapy for Palliation
of Painful Bone Metastases. J Natl Cancer Inst. 2005.

1. Ghasemi, F et al. (2021). Gene therapy for breast cancer treatment: Past, present, and future.
Journal of Cellular Physiology, 236(1), 74-91.

1. Wei, L. l. (2020). Gene therapy for breast cancer: A systematic review of phase I/II clinical

2.

3.

4. Mohamed Khalis, Karima EL Rhazi, Hafida Charaka. Femail breast cancer incidence and
mortality in Morocco: Comparison with other contries, Asian pacific journal of cancer
prevention, vol 17: 5211 –5216

5. FEUPI LEMOUOGUE WINNIE, Les antécédents familiaux de cancer du sein au Mali, Université
des sciences, des Technique et des Technologies de Bamako Faculté de Médecine et
d’odontostomatologie, 2019, P 26, Thèse de Doctorat en médecine

6. Razali sofiane, Cancer du sein suivi d'une population sous chimiothérapie, Faculté des
Sciences de la Nature et de la vie, Algérie, P04, 05. 28/06/2018. Mémoire de Master en
sciences Biologiques

TROJANI M., CONTESSO G., (1986), Anatomie pathologique des cancers du sein .In : HOERNI
B., Ed, Encyclopédie des cancers: les cancers gynécologiques et mammaires, Flammarion Médecine
Science, Paris, pp:277-291.
HAS. 2015. Haute Autorité de Santé. Actualisation du référentiel de pratiques de l’examen périodique
de santé. 2 avenue du Stade de France - 93218 Saint-Denis La Plaine CEDEX

CONTESSO G., GŒNEBRTIERE J-M (1997). Classification, anatomo-pathologique des cancers du

sein .In: Petit J-Y., VERERONESI U., NAHAI F., RIETJENS M., Eds, Chirurgie du cancer du sein:
diagnostique, curative et reconstructive. Copyright, France, pp : 55-66.

Namer M., Héry M., Serin D. et Spielmann M., 2006. Cancer du sein, Springer-Verlag France, Paris,
(469pages).

Fattaneh A.. Tavassoli. et Devile P., 2003. The WHO. Pathology and genetics. Tumors of the breast
and femal genital organs. IARCPress, Lyon, France, (430 pages).

MacGrogan, G., Vicent-Salomon, A. et Arnould, L, 2012. Pathologie mammaire. Congrès. (346 pages).

TROJANI M., CONTESSO G., (1986), Anatomie pathologique des cancers du sein .In : HOERNI B., Ed,
Encyclopédie des cancers: les cancers gynécologiques et mammaires, Flammarion Médecine Science,
Paris, pp:277-291.

MATHELIN C., GAIRARD B., BRETTES JP., RENAND R., (1997), Examen clinique du cancer du sein,
Encycl. Méd. Chir. (Elsevier, paris), Gynécologie, 865-C10, 1 lP.

Lakhani S-R., Ellis, I-O., Schnitt, S-J., Tan., P-H et Van de Vijer MJ, 2012. WHO classification of tumours
of the breast. 4th edition, IARCPress, Lyon, France, (240 pages).

Gérard-Marchant R. et Contesso G, 1981. Types histologiques des tumeurs du sein. Deuxième

édition, organisation mondiale de la santé Genève, USA, (71 pages).

-CABAROT E., (1998), tumeurs du sein Daly-Schveitzer N., Cabarrot E., Guimbard R., Mayol E, Eds,
Cancérologie Clinique 2éme édition, Masson, Paris, pp: 213-236.

CONTESSO G., GŒNEBRTIERE J-M (1997). Classification, anatomo-pathologique des cancers du

sein .In: Petit J-Y., VERERONESI U., NAHAI F., RIETJENS M., Eds, Chirurgie du cancer du sein:
diagnostique, curative et reconstructive. Copyright, France, pp : 55-66.

The International Agency for Research on Cancer. The Global Cancer Observatory (GCO), 2020.
http://gco.iarc.fr/

Yi - Sheng Sun, Zhao Zhao, zhang-NV Yang, Fang Xu, Risk factors and prevention of breast cancer,
2017, Center for Disease Control and Prevention, Hangzhou, China, International Journal of Biological
Sciences, Vol 13: 1387 – 1397

BOUCHELIT NESRINE, Étude du profil nutritionnel et détermination du statut oxydatif (prosoxydants)

chez les femmes atteintes d’un cancer du sein dans la région de Tlemcen‚ Université Abou Bekr Bel
kaïd Tlemcen‚ Faculté des Science de la nature, Vie, Terre et Univers‚ 24 juin 2014.p15. Thèse pour le
diplôme de Master en Biologie

Andre Nkondjock, Parviz Ghadirian, Facteurs de risque du cancer du sein‚2005‚ Institute of

Population Health, University of Ottawa, Ottawa, Ontario, Canada : 175–180
FISHER, Bernard, ANDERSON, Stewart, BRYANT, John, et al. Twenty-year follow-up of a randomized
trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment
of invasive breast cancer. New England Journal of Medicine, 2002, vol. 347, no 16, p. 1233-1241.

GIULIANO, Armando E., HUNT, Kelly K., BALLMAN, Karla V., et al. Axillary dissection vs no axillary
dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical
trial. Jama, 2011, vol. 305, no 6, p. 569-575.
i
Khalis, M., El Rhazi, K., & Charaka, H. (n.d.). Femail breast cancer incidence and mortality in Morocco:
Comparison with other countries. Asian Pacific Journal of Cancer Prevention, 17, 5211-5216.

Lemouogue Winnie, F. (2019). Les antécédents familiaux de cancer du sein au Mali [Doctoral dissertation,
Université des Sciences, des Techniques et des Technologies de Bamako Faculté de Médecine et
d’Odontostomatologie].

Sofiane, R. (2018). Cancer du sein suivi d'une population sous chimiothérapie [Master's thesis, Faculté des Sciences
de la Nature et de la Vie, Algérie].

Trojani, M., & Contesso, G. (1986). Anatomie pathologique des cancers du sein. In B. Hoerni (Ed.), Encyclopédie des
cancers: Les cancers gynécologiques et mammaires (pp. 277-291). Flammarion Médecine Science.

Haute Autorité de Santé. (2015). Actualisation du référentiel de pratiques de l’examen périodique de santé
[Report]. 2 avenue du Stade de France - 93218 Saint-Denis La Plaine CEDEX.

Contesso, G., & Gœnertiere, J.-M. (1997). Classification, anatomo-pathologique des cancers du sein. In J.-Y. Petit,
U. Veronesi, F. Nahai, & M. Rietjens (Eds.), Chirurgie du cancer du sein: Diagnostique, curative et reconstructive
(pp. 55-66). Copyright, France.

Namer, M., Héry, M., Serin, D., & Spielmann, M. (2006). Cancer du sein. Springer-Verlag France.
Tavassoli, F. A., & Devilee, P. (Eds.). (2003). Pathology and genetics of tumors of the breast and female genital
organs. IARCPress.

MacGrogan, G., Vicent-Salomon, A., & Arnould, L. (2012). Pathologie mammaire.

Trojani, M., & Contesso, G. (1986). Anatomie pathologique des cancers du sein. In B. Hoerni (Ed.), Encyclopédie des
cancers: Les cancers gynécologiques et mammaires (pp. 277-291). Flammarion Médecine Science.

Mathelin, C., Gairard, B., Brettes, J.-P., & Renand, R. (1997). Examen clinique du cancer du sein. Encyclopédie
Médico-Chirurgicale, Gynécologie, 865-C 10, 1-11.

Lakhani, S. R., Ellis, I. O., Schnitt, S. J., Tan, P.-H., & Van de Vijer, M. J. (2012). WHO classification of tumors of the
breast (4th ed.). IARCPress.
Gérard-Marchant, R., & Contesso, G. (1981). Types histologiques des tumeurs du sein (2nd ed.). Organisation
Mondiale de la Santé.

Cabarot, E. (1998). Tumeurs du sein. In N. Daly-Schveitzer, E. Cabarot, R. Guimbard, & E. Mayol (Eds.), Cancérologie
Clinique (2nd ed., pp. 213-236). Masson.

Contesso, G., & Gœnertiere, J.-M. (1997). Classification, anatomo-pathologique des cancers du sein. In J.-Y. Petit,
U. Veronesi, F. Nahai, & M. Rietjens (Eds.), Chirurgie du cancer du sein: Diagnostique, curative et reconstructive
(pp. 55-66). Copyright, France.

The International Agency for Research on Cancer. (2020). The Global Cancer Observatory (GCO). Retrieved from
http://gco.iarc.fr/

Sun, Y.-S., Zhao, Z., Yang, Z.-N., & Xu, F. (2017). Risk factors and prevention of breast cancer. International Journal
of Biological Sciences, 13, 1387-1397.

Bouchelit, N. (2014). Étude du profil nutritionnel et détermination du statut oxydatif (pros oxydants) chez les
femmes atteintes d’un cancer du sein dans la région de Tlemcen [Master's thesis, Université Abou Bekr Belkaïd
Tlemcen, Faculté des Sciences de la Nature, Vie, Terre et Univers

Nkondjock, A., & Ghadirian, P. (2005). Facteurs de risque du cancer du sein. Institute of Population Health,
University of Ottawa.
Baselga, J., Verma, S., Ro, J., Huober, J., Guardino, E., Fang, L., ... & Pegram, M. (2013). Abstract LB-63: Relationship
between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-
positive metastatic breast cancer (MBC). Cancer Research, 73(8_Supplement), LB-63.

Swain, S. M., Baselga, J., Kim, S. B., Ro, J., Semiglazov, V., Campone, M., ... & Cortés, J. (2015). Pertuzumab,
trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. New England journal of medicine, 372(8), 724-
734.

Denduluri, N., Chavez-MacGregor, M., Telli, M. L., Eisen, A., Graff, S. L., Hassett, M. J., ... & Giordano, S. H. (2018).
Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice
guideline focused update. Journal of Clinical Oncology, 36(23), 2433-2443.

Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., ... & Winer, E. P. (2018). 4th ESO–ESMO
international consensus guidelines for advanced breast cancer (ABC 4). Annals of Oncology, 29(8), 1634-1657.

The, A. T. A. C. (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant
treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. The
Lancet, 359(9324), 2131-2139.

Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., ... & Bowel Project
Investigators. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and
Bowel Project P-1 Study. JNCI: Journal of the National Cancer Institute, 90(18), 1371-1388.

Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S. A., Gelmon, K., ... & Slamon, D. J. (2016). Palbociclib and letrozole in
advanced breast cancer. New England journal of medicine, 375(20), 1925-1936.

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., ... & O’Shaughnessy, J.
(2016). Ribociclib as first-line therapy for HR-positive, advanced breast cancer. New England journal of
medicine, 375(18), 1738-1748.

Baselga, J., Campone, M., Piccart, M., Burris III, H. A., Rugo, H. S., Sahmoud, T., ... & Hortobagyi, G. N. (2012).
Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. New England Journal of
Medicine, 366(6), 520-529.

Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., ... & Conte, P. (2017). Olaparib for metastatic
breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine, 377(6), 523-533.

Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., ... & Gelber, R. D. (2005).
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine, 353(16),
1659-1672.

Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., ... & Dimitrov, N. V. (1997). Effect of
preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National
Surgical Adjuvant Breast and Bowel Project B-18. Journal of clinical oncology, 15(7), 2483-2493.

Wf, H. (2005). Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J.
Natl. Cancer Inst., 97, 798-804.
Ghasemi, F., Amiri-Yekta, A., Zare, H., Kafil, H. S., Yousefi, M., & Yousefi, B. (2021). Gene therapy for breast cancer
treatment: Past, present, and future. Journal of Cellular Physiology, 236(1), 74-91.

Wei, L., Jin, Y., Long, Y., Bai, Y., Mao, L., & Deng, Y. (2020). Gene therapy for breast cancer: A systematic review of
phase I/II clinical trials. Human Gene Therapy, 31(19-20), 1067-1081.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2011). Effect of radiotherapy after breast-conserving
surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801
women in 17 randomised trials. Lancet.

Giuliano, A. E., Hunt, K. K., Ballman, K. V., Beitsch, P. D., Whitworth, P. W., Blumencranz, P. W., ... Morrow, M. (2011).
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A
randomized clinical trial. Journal of the American Medical Association, 305(6), 569-575.

Alderman, A. K., Wilkins, E. G., Lowery, J. C., Kim, M., Davis, J. A., & Klassen, A. F. (2013). Long-term Results of Implant
Reconstruction Using One of Two Different Techniques. JAMA Surgery, 148(4), 344-351.

André, F., Slimane, K., Bachelot, T., Dunant, A., Namer, M., Barrelier, A., ... & Escudier, B. (2006). Adjuvant
Chemotherapy in Early Breast Cancer: Evidence-Based Practice. Journal of Clinical Oncology, 24(18), 1057-1063.

American Cancer Society www.cancer.org

National Cancer Institutewww.cancer.gov
World Health Organization -www.who.int
European Society for Medical Oncology www.esmo.org